{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04588480",
      "orgStudyIdInfo": {
        "id": "C4591006",
        "type": null,
        "link": null
      },
      "secondaryIdInfos": [],
      "organization": {
        "fullName": "BioNTech",
        "class": "INDUSTRY"
      },
      "briefTitle": "A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults",
      "officialTitle": "A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults",
      "acronym": null
    },
    "descriptionModule": null,
    "conditionsModule": null,
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "patientRegistry": false,
      "targetDuration": null,
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "interventionModelDescription": "Participants were randomized 3:1 to receive 2 intramuscular injections of 30 μg BNT162b2 or placebo 21 days apart. Participants were stratified by age: 20–64 years (n = 130) and 65–85 years (n = 30).",
        "primaryPurpose": "PREVENTION",
        "observationalModel": null,
        "timePerspective": null,
        "maskingInfo": {
          "masking": "TRIPLE",
          "maskingDescription": "Participants, investigators and other study staff were blinded; staff who dispensed/administered study medication were unblinded.",
          "whoMasked": [
            "PARTICIPANT",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 160,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": null,
    "outcomesModule": null,
    "eligibilityModule": null
  }
}